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Abstract
Background: Meta-analysis of gene expression microarray datasets presents significant challenges for statistical analysis. We
developed and validated a new bioinformatic method for the identification of genes upregulated in subsets of samples of a
given tumour type (‘outlier genes’), a hallmark of potential oncogenes.
Methodology: A new statistical method (the gene tissue index, GTI) was developed by modifying and adapting algorithms
originally developed for statistical problems in economics. We compared the potential of the GTI to detect outlier genes in
meta-datasets with four previously defined statistical methods, COPA, the OS statistic, the t-test and ORT, using simulated
data. We demonstrated that the GTI performed equally well to existing methods in a single study simulation. Next, we
evaluated the performance of the GTI in the analysis of combined Affymetrix gene expression data from several published
studies covering 392 normal samples of tissue from the central nervous system, 74 astrocytomas, and 353 glioblastomas.
According to the results, the GTI was better able than most of the previous methods to identify known oncogenic outlier
genes. In addition, the GTI identified 29 novel outlier genes in glioblastomas, including TYMS and CDKN2A. The over-
expression of these genes was validated in vivo by immunohistochemical staining data from clinical glioblastoma samples.
Immunohistochemical data were available for 65% (19 of 29) of these genes, and 17 of these 19 genes (90%) showed a
typical outlier staining pattern. Furthermore, raltitrexed, a specific inhibitor of TYMS used in the therapy of tumour types
other than glioblastoma, also effectively blocked cell proliferation in glioblastoma cell lines, thus highlighting this outlier
gene candidate as a potential therapeutic target.
Conclusions/Significance: Taken together, these results support the GTI as a novel approach to identify potential oncogene
outliers and drug targets. The algorithm is implemented in an R package (Text S1).
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Introduction
The identification of genes associated with cancer development
and progression is a central goal for many microarray data analysis
projects [1–4]. Oligonucleotide microarrays offer clinicians and
researchers the ability to analyze gene expression on a genome-
wide scale. Expression arrays have been widely used in biological
and clinical transcriptome studies for over a decade, and vast
amounts of data have been accumulated in the public domain. For
example, the Gene Expression Omnibus (GEO) database (http://
www.ncbi.nlm.nih.gov/geo/) currently contains over 9247 ex-
pression studies in which human samples have been analyzed with
gene expression microarrays [5].
Most microarray studies have focused on the identification of
differentially expressed genes, using a panel of test and control
samples collected at the same time and analyzed on a single
platform. Most of these studies have been based on relatively
homogeneous datasets consisting of comparably small numbers of
samples. However, when results from such individual studies are
compared with each other, the overlap of the differentially
expressed gene sets is often minimal and disappointing. In order to
identify consistently differentially expressed genes based on robust
statistics, it is advisable to systematically combine multiple public
datasets. The power of this ‘meta-analysis’ strategy has been
demonstrated in the case of ArrayExpress [6], the Oncomine
database [7], GeneSapiens [8], the Connectivity Map database [9]
and several others. Large-scale integrated microarray datasets
typically combine strongly diverging datasets based on different
experimental conditions, independent cohorts of samples, varying
sample preparation methods and labelling methods or scanner
settings, and even different microarrays or microarray platforms.
These multiple layers of variability pose a significant challenge to
the statistical methods applied in meta-analyses. For example, the
oligonucleotide array design utilized by Affymetrix, the leading
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manufacturer of expression arrays, has significantly changed over
the last decade, resulting in many datasets with a variant probe set
content and addressing variable numbers of genes. Several groups
have already described methods for the integration of such diverse
datasets [10], [11], [8]. As a result of these developments, there is a
need for improved algorithms that facilitate the successful mining
of heterogeneous multi-study or meta-analysis datasets.
Out of the many statistical methods used for the identification of
differentially expressed genes [12,13], the t-statistic has been one
of the most basic and straightforward approaches for the analysis
of individual studies. More recently, methods have been developed
to detect differentially expressed genes in a subset of samples.
These include cancer outlier profile analysis (COPA) [14], the
outlier sum (OS) statistic [15] and the outlier robust t-statistic
(ORT) [13]. COPA and OS statistics were derived from the t-
statistic by replacing the mean and standard errors with the
median and median absolute deviations, respectively. ORT was
proposed as a more robust statistic that utilizes the absolute
difference of each expression value from the median instead of the
squared difference of each expression value from the average.
In general, outlier analysis offers a unique and powerful
approach for the identification of key pathogenetic genes involved
in a subset of disease samples. The strength of cancer outlier
profile analysis was powerfully demonstrated by the identification
of the TMPRSS2-ERG fusion oncogene in prostate cancers [14],
considered a major breakthrough in cancer genetics. Another
classic example of a typical cancer outlier gene is ERBB2/HER-2
[16], an important therapeutic target over-expressed in about 20%
of human breast cancers. This is currently utilized for the therapy
of HER2+ breast cancer patients with the therapeutic Herceptin
antibody. Thus, genes generally expressed at low levels in normal
samples, but over-expressed in a subset of cancer samples
(although not all tumours), often represent potential drug targets
of therapeutic interest, and may point to biologically different and
diverse cancer subtypes that may require a specific form of
individualized therapy.
A gene showing over-expression in a subgroup of disease
samples based on a cut-off threshold is defined as an outlier
(Figure 1). Our aim was to find genes that are differentially
expressed in a subset of test samples as compared to the controls.
Here, we describe a novel statistical method for identifying genes
with outlier expression in large-scale microarray data integration
studies and compare this method with existing algorithms. These
comparison methods include the t-statistic, cancer outlier profile
analysis (COPA), the outlier sum (OS) statistic and outlier robust t-
statistic (ORT).
COPA and OS statistics were derived from the t-statistic by
replacing the mean and standard errors used in the t-statistic with
the median and median absolute deviations, respectively. ORT has
been proposed as a more robust statistic that utilizes the absolute
difference of each expression value from the median instead of the
squared difference of each expression value from the average.
In this study, we adapted an existing method from economics
(the poverty index) with a comparable goal, addressing the
question of how many people live below the poverty line in any
given country, a formula developed for socioeconomic studies by
Amartya Sen [17]. To adapt this algorithm for gene expression
analysis, we inverted the original question here by asking, ‘‘in
how many samples from the same body part is a gene X
expressed above a fixed cut-off threshold?’’ Since the index is
determined as a robust proportion of outlying samples, we
assume that every gene is represented by an adequate number of
samples. To this end, our aim was to establish an index that
determines whether there is significantly increased gene expres-
sion in a sub-group of disease samples compared to the normal
control group, without the restriction of making distribution
assumptions for the various group populations. In preliminary
studies, we observed that poverty indices derived from economics
are well suited to measure the proportion of outlying samples
within the disease sub-group relative to the reference group.
Motivated by these observations, we modified the original
poverty index formula [17], and in this paper we introduce the
gene tissue index (GTI). The GTI is then systematically
compared with the existing methods, i.e. t-statistics, COPA, OS
and ORT. Furthermore, we compare the outlier detection
capability of existing methods with the GTI using a simulated
Figure 1. Illustration of a typical oncogene outlier profile. An example of a gene with high expression in the cancer group compared to the
normal group. The circle in the cancer group refers to a subset of samples with high expression of this gene, while the circle in the normal group
refers to a subset of normal samples, with low expression. The boxplot in B illustrates the concept of data outliers in standard terminology.
doi:10.1371/journal.pone.0017259.g001
Gene Tissue Index Outlier Algorithm
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e17259
and real clinical large-scale integrated dataset. No comparative
studies are currently available to support the suitability of the
existing methods for the analysis of real, large-scale integrated
meta-datasets such as those collected in the GeneSapiens[8]
database.
Materials and Methods
Existing Statistical Methods
Let xij be the expression values for genes j~1,2, . . . . . . ,p and
samples i~1,2, . . . . . . ,n. We assume that the gene expression
samples are obtained from two different groups (k~1 and k~2),
where n~n(1)zn(2). In our case, n(1) represents the number of
samples from the normal group and n(2) represents the number of
samples from the cancer group. Let Ck be the set of indices of the
observations in group k, for k = 1 and 2.
t-statistic
The formula for the standard unpaired t-statistic is:
Tj~
x(2)j { x
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j
sj
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assuming that the within-group standard deviations for the two
groups are equal.
The two-sample t-test assumes that all disease samples for a
particular gene are over-expressed. This assumption is not the case
in cancer gene outlier analysis, where the genes are only assumed
to be over-expressed in a subset of samples within the disease
group that is assumed to be over-expressed [13].
Cancer Outlier Profile Analysis (COPA)
The COPA [13,14,18–21] statistic is defined as the rth
percentile of the disease samples’ standardized expression values
qr(~xij : i[C2), using r = 75, 90, or 95 as suggested by the authors.
Observations for gene j are standardized by subtracting the
median medj from each expression value (xij) divided by the
median absolute deviation madj
~xij~
xij{medj
madj
, i~1, . . . . . . ,n, j~1, . . . . . . ,p, ð2:3Þ
where, medj is the median and madj is the median absolute
deviation of gene j’s expression values.
medj~mediani~1,...n(xij),
madj~1:4826 mediani~1,...,n xij{medj
  ,
where the product of madj and the constant 1.4826 is approxi-
mately equal to the standard error for normally distributed
random variables.
The approach used in the COPA statistic addresses the problem
of more accurately identifying genes with an outlier population
than the t-statistic.
The COPA statistic is described as
qr(~xij : i[C2)~
qr(xij : i[C2){medj
madj
, ð2:4Þ
where the rth percentile of the disease samples is qr(xij : i[C2).
Compared to the t-statistic, COPA intuitively replaces the
normal sample mean by the all-sample median medj, the sample
standard error sj by the median absolute deviation madj, and the
disease sample mean by the rth percentile qr(xij : i[C2).
It is evident that the COPA statistic may not be very robust,
since a fixed rth sample percentile is almost equal to using
information from a single sample.
Outlier Sums (OS)
The outlier sums statistic was introduced as an improvement
over the COPA statistic. Here, the OS statistic [13,15,21] was
proposed to replace the rth percentile with a sum over the outlier
samples from the disease group above a given cut-off. The OS
statistic was designed to lower the false discovery rate (FDR) of
COPA, as noted by Wu [13]. OS standardizes each expression
value of gene j (xij) through dividing the result of (xij – medj) by
madj. However, only expression values above a given cut-off are
utilized for the final score.
OS scorej ~
P
i[Oj
(xij{medj)
madj
, ð2:5Þ
where Oj is the set of outlier samples from the disease group
defined by the following heuristic criterion:
Oj ~ i : i[C2,xijwq75(xmj : m~1,:::::,n)z

IQR(xmj : m~1,::::,n)
	
,
ð2:6Þ
where m refers to samples 1,2.....,n1,n1+1,....n.
Outlier Robust t-statistic (ORT)
The outlier robust t-statistic[13,19,21] is a direct robust general-
ization of the two-sample t-statistic. With ORT, the sample mean is
replaced with the median and the squared difference is replaced with
the absolute difference. The overall median used as a common
estimate for the two group medians was suggested to be inefficient,
since the normal and disease samples are known to be different. The
ORT statistic was therefore proposed to replace the overall median
estimate used in calculating the COPA and OS score with a median
calculated from the group median-centred expression values.
xij{med
(1)
j
 , i~1,:::::,n1; xij{med (2)j
 , i~n1z1,:::::,n,
where med
(1)
j and med
(2)
j are the sample medians for normal and
disease groups.
med
(1)
j ~mediani[C1 (xij), med
(2)
j ~mediani[C2 (xij):
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The median absolute deviation will then be estimated as
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which was proved to be similar to the pooled sample variance
estimate
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Here, the average (avg) is replaced with the sample median, and
the squared difference is replaced with the absolute difference as a
more robust estimate of the variance.
ORT is then described as
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where R is the set of outlier disease samples for gene j defined by
Rj~ i : i[C2,xijwq75(xmj : m~1,:::::,n1)z

IQR(xmj : m~1,::::,n1)
	
,
ð2:9Þ
where m refers to samples 1,2…..,n1.
It should be noted that only the normal group samples are used
to estimate outliers when calculating an ORT score.
Gene Tissue Index (GTI)
The GTI algorithm was originally used to calculate an index for
a single treatment group k based on a standard cut-off. In this
study, there was no defined standard cut-off per gene j for every
normal tissue. Therefore, we defined a cut-off (B) based on the
expression of gene j among all samples (n). These samples were
obtained from one body part or tissue type such as the breast of
normal (k = 1) and cancer-affected (k = 2) individuals. We then
asked whether the proportion of samples above the cut-off is larger
than it should be. Our choice of B is the standard statistical outlier
cut-off (q75+IQR). We propose the following score, which weighs
the proportion of outliers by a robust measure of how outlying the
outliers are in a single group:
GTI
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where T
(k)
j is the number of samples with expression values above
the cut-off (number of elements in set O
(k)
j ), n
(k)
j is the total number
of samples in group k and A
(k)
j is the average expression of the
samples above the cut-off for gene j.
We write
IQR(xij : i~1,::::::,n)~
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for the interquartile range (IQR).
Expanding the definition of the GTI and substituting our choice
of B, we get
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where x(k)j is the mean of ‘outlier samples’ in the group (k = 1 or
k = 2) for genes j~1, . . . . . . ,p,
x(k)j ~
X
i[O(k)
j
xij
n
,
where the set O
(k)
j consists of the outliers in group k. The set O
(k)
j is
defined using the following criterion:
O
(k)
j ~ i : i[Ck,xijwq75(xmj : m~1,:::::,n)z

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,
ð2:12Þ
where m refers to samples 1,2, …..,n(1),n(1)+1, …..n.
We calculate the actual GTI scores for each group k and gene j
multiplied by 100, as this makes them more readable.
Finally, the index per gene is a direct association between two
groups defined by GTIj~GTI
(2)
j {GTI
(1)
j , where 2 and 1
represent the grouping. The index GTIj can be a large positive
number if there are outliers in the disease group 2 or a large
negative number if there are outliers in the normal control group
1. All samples (cancer and normal combined) are then used to
determine the cut-off point for each gene. As in the existing
methods, we use permutations to estimate the null distribution and
p-values of the GTI.
Microarray data
The pre-processed Affymetrix transcriptome data utilized in this
study were derived from the GeneSapiens database [8], and were
acquired from multiple public repositories such as the Gene
Expression Omnibus (GEO). In GeneSapiens, different Affymetrix
array generations were normalized and combined to form a single
large-scale multi-study dataset. It should be noted that the data in
GeneSapiens are normalized first within a sample and then
between samples using an Array Generation-based gene Centering
(AGC) normalization [8]. The outlier analysis performed for the
GTI evaluation study covered a total of 16 868 human genes, each
represented by a different number of normal and cancer samples
in the database. As the compositions of microarrays are regularly
updated to incorporate new genes with improved target sequences,
it is evident that combining data from different generations of the
same microarray platform will generally result in largely varying
numbers of samples per gene. We compared the log-transformed
data of the normal group with the cancer group and performed
five separate tests using the five methods introduced earlier.
Cell culture and reagents
Human glioblastoma cell lines A172 and U87-MG were
obtained from the ECACC (European Collection of Cell Cultures,
UK), the LN-405 cell line was obtained from DSMZ (Deutsche
sammlung von microorganismen und zellkulturen GmbH, Ger-
many), and the U373-MG and astroglia SVG p12 cell lines from
the ATCC (American Type Culture Collection, VA, USA). The
Gene Tissue Index Outlier Algorithm
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A172, LN-405 and U373-MG cell lines were cultured in DMEM
with 4500 mg/L glucose, 10% FBS, 2 mM L-glutamine and
penicillin-streptomycin. U373-MG cells were supplemented with
300 ng/mL hygromycin. The U87-MG and SVGp12 cell lines
were cultured in EMEM with 2 mM L-glutamine, 1 mM sodium
pyruvate, 0.1 mM non-essential amino acids, 1.5 g/L sodium
bicarbonate, penicillin-streptomycin and 10% FBS.
The antifolate drugs used in EC50 determinations were 5-
fluorouracil (Sigma-Aldrich Co, St. Louis, Missouri), gemcitabine
(trade name: Gemzar, Eli Lilly, Indianapolis, Indiana) and
raltitrexed (trade name: Tomudex, Astra Zeneca, London, UK).
Determination of the Median Effective Concentration
(EC50)
The human glioblastoma cell lines A172 and U87-MG were
obtained from the ECACC (European Collection of Cell Cultures,
UK), LN-405 cell line was obtained from DSMZ (Deutsche
Sammlung fuer Microorganismen und Zellkulturen GmbH,
Germany), and the U373-MG and SVG p12 cell lines were
purchased from the ATCC (American Type Culture Collection,
VA, USA). The A172, LN-405 and U373-MG cell lines were
cultured in DMEM with 4500 mg/L glucose, 10% FBS, 2 mM L-
glutamine and penicillin-streptomycin. U373-MG cells were
supplemented with 300 ng/mL hygromycin. The U87-MG and
SVGp12 cell lines were cultured in EMEM with 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino
acids, 1.5 g/L sodium bicarbonate, penicillin-streptomycin and
10% FBS. The antifolate drugs used in EC50 determinations were
5-fluorouracil (Sigma-Aldrich Co, St. Louis, Missouri), gemcita-
bine (trade name: Gemzar, Eli Lilly, Indianapolis, Indiana) and
raltitrexed (trade name: Tomudex, Astra Zeneca, London, UK).
Results
The suitability of existing outlier methods for the analysis of
large-scale multi-study datasets is not only measured by the
absolute statistical quality of the results obtained in theoretical
settings, but strongly depends on a number of technological and
practical issues. In this respect, it is mandatory to meticulously test
whether such methods can be used for the analysis of extremely
large-scale integrated microarray datasets. Currently, multi-study
datasets such as those collected in GeneSapiens, or the clinical
data sets provided by large-scale international cancer profiling
consortia such as TCGA or ICGC, easily contain hundreds to
several thousands of samples. The tendency towards large data sets
will further increase with the progress of these integrated
approaches, and with the introduction of next-generation genome
sequencing technologies in cancer research. Some existing outlier
methods may not be suitable to handle matrices with very many
sample numbers, in particular if the data points available within
these sets vary gene by gene. Even given the suitability of certain
statistical approaches for successful outlier identification, the
process may be exceedingly slow and may not be suitable for
repeated application after every update to a database. For these
reasons, we decided to evaluate the suitability of the GTI and the
existing methods for identifying outliers in complex multi-study
datasets.
Comparison of the new GTI method with previously
described outlier identification methods in a simulated
single study dataset
First, to compare the GTI method with previously described
outlier identification methods, we conducted simulation studies
using ORT, OS, and COPA methods with a fixed statistical
outlier cut-off (q75+IQR). In addition, the t-statistic was
considered; however, this method did not require any cut-off
selection. For the simulation, an artificial dataset was generated
representing 1000 genes assuming an equal number of normal and
cancer samples (n(1) = n(2) = 30), in which all expression values were
drawn from a standard normal distribution. Next, we generated
expression values for a gene assumed to be differentially expressed
by adding a constant, m, to the expression values in only the first k
cancer samples (k = 1, 10 or 30), where k equals the number of
outlier samples, and used this value as the true positive (TP). The
true positive and false positive (FP) values were calculated based on
50 simulations.
In each simulation, a p-value was calculated as the proportion of
genes with a score greater than that of the true positive. After
collecting the 50 p-values, the true positive rate corresponding to a
given false positive threshold was estimated as the proportion of
simulations identifying the true positive gene using the false
positive threshold. In other words, the generated p-value was not
greater than the false positive rate. We varied the values of k
(k = 30, 20, 10, 1) to simulate how the five statistical methods
would perform in these different artificial cases. This procedure
was repeated for each method as well as each dataset simulated
with a varying value of k. The data from the simulations were used
to calculate the true positive rate based on a given false positive
threshold. These results are summarized in Table S1. The data in
the Excel sheet named ‘‘ROC curve data from simulations’’ were
used to construct the receiver operating characteristic (ROC)
curves illustrated in Figure 2. Each curve generated for each
method refers to a defined true positive rate for a particular
method versus the false positive rate. An optimal method should
generate large areas under the curve (AUC) for each simulated
dataset.
The results presented in Figure 2 suggest that the GTI performs
equally well to the other methods under single study settings. The
first case of k = 1 (1 outlier in 30 samples) may exist, but is often
neglected. The last case of having all samples in the disease group
(k = 30) over-expressed is a typical profile for disease biomarkers
rather than outlier expression.
The most interesting case of having k= 10 (10 outliers in 30
samples) showed that all methods were equally suited to identify
the outliers. To visualize our approach, Figure S1 shows the
simulated expression values of the top 12 genes ranked by the
GTI. However, according to the results presented in Figure S1, all
of these genes showed a strong outlier population in the cancer
group.
Importantly, all of the simulations used to derive these results
were carried out in a single study setting. However, multi-study
data sets are becoming increasingly common and powerful
resources, and it would be practical to test the applicability of
these methods to multi-study datasets. To achieve this goal, our
systematic analysis was extended by using pre-processed data from
the GeneSapiens database.
Application to a large-scale glioma microarray integrated
dataset
The GTI and the ORT, OS, and COPA methods were then
tested with publicly available microarray datasets derived from
central nervous system (CNS) tissues and tumours. We chose CNS
tissue samples because there is an enormous wealth of data on
glioblastoma in public repositories such as the Cancer Genome
Atlas (TCGA) and GEO. Gliomas make up a group of primary
CNS tumours that arise from glial cells. We focused on two
subgroups of gliomas, anaplastic astrocytoma (WHO grade III) (74
samples) and glioblastoma multiforme (GBM, WHO grade IV)
Gene Tissue Index Outlier Algorithm
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(353 samples). We used Affymetrix microarray data from healthy
CNS tissues (392 samples) as a reference. The overlap of the top
100 genes identified by the GTI, COPA and the OS statistic is
presented in a Venn diagram in Figure 3. The results indicate that
approximately half of the genes could be identified by all three of
these methods. COPA and the GTI showed more overlap than the
GTI and OS; however, the OS statistic shared more genes with
COPA than the GTI. The GTI identified 29 potentially novel
outlier genes not identified in the top 100 by the other methods.
Naturally, we wanted to focus on these 29 unique genes and
further validate the GTI method by examining the value of these
candidates in the cancer biology of glioma (see section on
validation of targets below).
More specifically, we examined genes previously known to be
over-expressed in and/or associated with the development,
maintenance, and progression of glioblastoma multiforme and
anaplastic astrocytoma and that were identified in the top 100 by
any of the methods, as illustrated in Table 1. COPA identified
seven known genes among the top 100 followed by the GTI (6),
OS (4), ORT (3) and finally the t-statistic (2) (Table 1). All six genes
identified by the GTI were also identified by COPA. More
significantly, the GTI did not identify GFAP, a known
differentiation marker for normal cells of astroglial origin as well
as a glioma marker, which ranked highly using COPA (Table 1)
[22,23]. Next, we compared CDKN2A, which was the gene
ranked lowest by the GTI (Table 1), with GFAP, which was only
ranked highly by COPA. The distribution plots showed interesting
differences between the respective gene expression profiles. While
the gene expression levels of CDKN2A (ranked 71 with COPA
and 92 with the GTI) showed a significantly clearer outlier
population than GFAP (ranked 29 with COPA and 1866 with the
GTI) (Figure 4), GFAP also showed a relatively high level of
Figure 2. ROC curves for four different numbers of outliers. Receiver operating characteristic (ROC) curves from the above simulation study
comparing the five statistics. One cancer gene is over-expressed by m units equal to 2 in k of the 30 samples. ROC curves are plotted based on 50
simulations. K refers to the number of outliers in the disease group.
doi:10.1371/journal.pone.0017259.g002
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expression in the normal samples, indicating that this gene may in
fact not be relevant for cancer progression. This pattern was
similar for many of the genes uniquely identified by COPA,
contradictory to its purpose of identifying outliers.
To further examine the relevance of GFAP identified by COPA,
but not the GTI, we also examined the expression of GFAP in
tissue specimens. Specifically, immunohistochemical data from the
Human Protein Atlas [www.proteinatlas.org] (HPA) confirmed
that GFAP is expressed in all normal brain as well as brain cancer
samples, and hence cannot be considered a ‘cancer outlier’ (data
not shown). Briefly, and as illustrated by the GFAP mRNA
expression profile, although not the only example, a high COPA
score did not necessarily imply a significant outlier expression
difference between the normal and cancer groups (Figure 4).
The observed results for GTI are to some extent in agreement
with the genomic and transcriptional aberrations linked to
gliomas. This is the case for some of the 14 genes presented in
Table 2, which are known to be amplified or lost in significant
subsets of gliomas. The ranks of selected oncogenes and tumour
suppressor genes reported to be involved in glioblastoma multi-
forme (GBM) and anaplastic astrocytoma are presented in Table 2.
It is apparent that some of the amplified and/or over-expressed
genes, such as CDKN2A and CDKN2B, acquired high GTI
scores, while commonly deleted genes such as PTEN acquired low
scores. Interestingly, the GTI and COPA identified these over-
expressed genes almost equally well, while all other methods (OS,
ORT, t-statistics) performed significantly less well. The main
difference between the GTI and COPA therefore appears to be
the successful exclusion of false positive genes such as GFAP,
which may be highly expressed in the glioma samples, but do not
represent true outliers.
The glioblastoma large-scale integrated dataset used in this
work contains varying numbers of samples per gene due to the
combining of different generations of Affymetrix platforms. To
predict whether the final score is affected by the varying number of
samples, Spearman’s rank correlation coefficient was calculated
for each method from the scores of each method and the number
of samples per gene (Table 3). A correlation value close to zero
means that the final score of the method does not depend on the
number of samples. As revealed in Table 3, OS and ORT statistics
resulted in higher correlation values with the total number of
samples, the number of normal samples and the number of cancer
samples compared to GTI, the t-statistic and COPA.
Overall, the GTI seemed to perform best in comparison to the
other methods in identifying genes with an outlier profile among
the glioma large-scale integrated dataset. Notably, when there are
datasets with varying numbers of samples for different genes, the
GTI, but not COPA, OS, ORT or the t-statistic, produced
comparable scores among differentially expressed genes.
Biological validation of some GTI top outliers
As stated above and shown in Table S2, 29 outlier genes were
uniquely identified by the GTI (Table S2). Interestingly, among
these 29, thymidylate synthase (TYMS) was the second best hit on
the list (Table 4, GTI score 35, COPA score 105, OS score 1864,
ORT score 1646), indicating high expression of this gene in many
but not all glioblastomas, but generally low expression levels across
the vast majority or all of the normal samples. GTI may therefore
identify a putative subset of cancers that may particularly profit
from therapy targeting the TYMS gene, which may not be the
case for all of the glioblastoma patients.
However, there are no publications to date linking TYMS to
glioblastoma. In fact, only 7 of the 29 genes identified (24%) had
been previously linked to glioblastoma in two or more publications
(Table 4). Similarly, as many as 18 out of the 29 genes (62%) were
linked to oncogenic functions in other cancers (Table 4). These
observations suggest that the GTI identified more previously
Figure 3. Venn diagram showing overlapping genes. The three
sets of the top 100 genes only partially overlap, which means that at
least one of them has many false positives or false negatives.
doi:10.1371/journal.pone.0017259.g003
Table 1. Genes known to be associated with anaplastic
astrocytoma and glioblastoma multiforme (GBM) out of the
top 100 genes from every method after ranking according to
the score.
Methods Rank Gene GTI COPA OS ORT t-test
GTI 51 VEGFA 32 56 1 766
92 CDKN2A 71 212 15 2846
31 EGFR 33 125 41 1411
32 IL13RA2 31 102 354 1664
27 IGFBP2 4 10 3373 51
65 CHI3L1 9 22 11962 405
COPA 32 VEGFA 51 56 1 766
71 CDKN2A 92 212 15 2846
33 EGFR 31 125 41 1411
31 IL13RA2 32 102 354 1664
4 IGFBP2 27 10 3373 51
9 CHI3L1 65 22 11962 405
29 GFAP 1866 487 11990 6052
OS 56 VEGFA 51 32 1 766
10 IGFBP2 27 4 3373 51
22 CHI3L1 65 9 11962 405
71 PDGFC 1301 768 11968 24
ORT 1 VEGFA 51 32 56 766
15 CDKN2A 92 71 212 2846
41 EGFR 31 33 125 1411
t-test 51 IGFBP2 27 4 10 3373
24 PDGFC 1301 768 71 11968
The rank column here refers to the position of the gene if all the 100 genes are
sorted in descending order so that we have the first gene being the one with
the highest outlier score for a particular method. Some of the methods, such as
ORT, identified very few known outlier genes among the top 100.
doi:10.1371/journal.pone.0017259.t001
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known oncogenes critical for the progression of other (e.g.
epithelial) cancer types, which nevertheless have not been
associated with glioblastoma. We also investigated protein staining
images for 19 of the 29 genes uniquely identified by GTI, available
in the human protein atlas database (HPA) (Table 4).
In contrast to the 29 unique GTI-identified candidates
including TYMS, cyclin-dependent kinase inhibitor 2A, isoform
4/p16 (CDKN2A), was flagged by most of the methods (GTI score
92, COPA score 71, OS score 212, ORT score 15). This should
therefore represent a cancer-relevant gene that is over-expressed in
subsets of many different cancer types, but is not particularly
specific for glioblastoma. For both CDKN2A and TYMS,
immunohistochemical staining images were available from the
HPA [24,25], and were used to validate the outlier gene expression
(Figure 5), assuming that differences in mRNA levels actually
reflect differences in protein expression. Indeed, CDKN2A and
TYMS showed strong positive staining in a subset, but not in all
cancer samples (Figure 5). The Human Protein Atlas illustrated
moderate or strong staining in 9 of 12 samples for TYMS and 5
out of 12 glioma samples for CDKN2A. For CDKN2A, 7 out of
12 glioma samples showed negative staining, possibly reflecting the
fact that CDKN2A is often deleted in gliomas. Characteristic for a
distinct outlier gene is the observation that one subgroup of
Table 2. Ranks of known anaplastic astrocytoma (grade III)
and glioblastoma multiforme (GBM grade IV) genes.
No Symbol
No. of
PubMed
refs GTI COPA OS ORT t-test
1 GFAP 965 1866 29 487 11990 6052
2 EGFR 904 31 33 125 41 1411
3 OLIG2 44 3598 2773 13557 13643 5053
4 CHI3L1 19 65 9 22 11962 405
5 IQGAP1 6 1093 1141 1313 3314 1231
6 IGFBP2 61 27 4 10 3373 51
7 IL13RA2 2 32 31 102 354 1664
8 MDM2 169 7088 9138 6439 3623 7762
9 RB1 38 1869 2862 2621 2308 1788
10 CDKN2A 367 92 71 212 15 2846
11 CDKN2B 46 778 2790 418 244 3259
12 PTEN 471 5476 4524 2479 2557 3895
13 TP53 291 719 1325 1386 3342 709
14 MCM3 1 2673 3290 2837 1939 1484
The third column shows the number of articles as of 27/04/10 linking each gene
to glioblastoma multiforme. Columns 4 to 8 present the rank of each gene
among the five methods.
doi:10.1371/journal.pone.0017259.t002
Table 3. Spearman’s rank correlation between the number of
samples and ranks of genes per method.
All samples
Count of normal
samples
Count of cancer
samples
GTI 20.073 20.056 20.058
t-test 20.059 20.054 20.072
COPA 0.042 0.022 0.069
OS 0.25 0.20 0.29
ORT 0.22 0.18 0.26
For each method, the scores are converted into ranks. Spearman’s rank
correlation is calculated between each method and the number of samples.
doi:10.1371/journal.pone.0017259.t003
Figure 4. GeneSapiens database gene plots for GFAP and CDKN2A. The above plots are from the publicly available GeneSapiens database.
The y-axis defines the expression level of each gene while the x-axis defines the number of samples per gene. We compared the expression of each
gene among normal and cancer samples.
doi:10.1371/journal.pone.0017259.g004
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samples showed very strong and uniform staining, while the
remainder of the samples only showed very weak or negative
staining, similar to the normal expression of this gene in non-
malignant, control samples. Significantly, similar outlier protein
staining patterns were observed in 17 out of the 19 genes (90%) for
which a panel of immunostaining histology images was available in
the HPA (Table 4).
TYMS is a known target of many antifolate drugs, such as 59-
fluorouracil (5FU) and gemcitabine. These drugs have been tested
for the treatment of GBM patients, but have offered little general
advantage over other treatment options [26–28]. Whereas 5FU
and gemicitabine also inhibit RRM2 (ribonucleoside-diphosphate
reductase M2 subunit) and DHFR (dihydrofolate reductase) [29],
the new drug raltitrexed may be more specific to TYMS, but no
published data are available for glioblastoma treatment.
Assuming that the concentration of the target gene would
correlate with the sensitivity of cancer cells against the specific
drug, we determined the median effective concentration (EC50)
values for these three anti-folate drugs in cytotoxicity/cell
proliferation assays with four established GBM cell lines and an
immortalized foetal astrocyte cell line, SVGp12. Gemcitabine and
the TYMS-specific raltitrexed showed EC50 values on the nM
scale (Figure 6) against the GBM cell lines which all expressed
significant levels of TYMS, whereas 5FU was only effective at
1000-fold higher concentrations (data not shown). The immortal-
ized normal foetal astrocyte SVGp12, which only expressed
TYMS at low levels, was 4- to 20-fold less sensitive to raltitrexed
than any of the cancer cell lines. This suggests that TYMS may be
a therapeutic target for glioma cells, and further studies to test the
efficacy of a folate-targeting drug in gliomas showing outlier
expression for TYMS should be undertaken.
Taken together, the results suggest that the detection of gene
outliers with the GTI may provide complementary information on
potential oncogenic genes in tumour tissue samples, and that these
genes may be biologically relevant and associated with tumour
progression.
Table 4. Assessing GTI-unique hits in relation to key terms (‘‘glioblastoma’’ and ‘‘oncogene’’) and their HPA staining images.
No Symbol
No. of PubMed refs,
keyword ‘‘glioblastoma’’
No. of PubMed refs,
keyword ‘‘oncogene’’ Rank GTI
HPA outlier
positive
HPA outlier
negative
HPA outlier
inconclusive
1. LY96 1 4 29 - - -
2. TYMS 0 5 37 3
3. RASEF 0 0 42 3
4. SRPX2 1 0 44 3
5. VMO1 0 0 45 - - -
6. TK1 5 8 52 3
7. CCNB2 2 50 57 3
8. TREM1 2 3 58 3
9. CHAC2 0 0 64 - - -
10. CCDC102B 0 0 70 - - -
11. VCAM1 0 4 71 3
12. PRC1 2 39 72 3
13. NCAPG 0 0 75 - - -
14. NOD2 0 6 76 - - -
15. NPW 0 4 79 - - -
16. IL32 1 7 80 3
17. GALK1 0 0 81 3
18. EZH2 6 81 82 3
19. WHSC1 2 11 84 3
20. TTK 0 16 89 3
21. TFPI 11 18 90 3
22. PLEKHA4 0 0 91 - - -
23. EHD2 0 0 93 - - -
24. NMU 1 58 94 3
25. C6orf173 0 0 95 - - -
26. UBE2T 0 1 96 3
27. PROM1 1 1 97 3
28. ARSJ 0 0 99 3
29. SOCS2 1 37 100 3
Most of the 29 genes uniquely identified by the GTI have not been associated with oncogenic processes in glioblastoma, although there were several articles listed in
PubMed linking them to oncogenic processes in other cancers as of 01/12/2010. The majority of the genes show variable immunohistochemical staining patterns in the
Human Protein Atlas (HPA).
doi:10.1371/journal.pone.0017259.t004
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Discussion
In summary, we have shown how our newly-developed
algorithm can be successfully utilized for the robust detection of
outlier gene expression in cancers. The GTI performs particularly
well with heterogeneous large-scale datasets that contain either
variable numbers of samples between the groups being compared
or variable numbers of informative samples for different genes.
Figure 5. Human Protein Atlas images illustrating outlier gene expression. Glioma specimens were grouped into four categories of staining
intensity (protein expression): i) negative, ii) weak, iii) moderate and iv) strong; a) and e) show staining of a normal sample. The upper panel TYMS/
CDKN2A shows the staining of cancer samples for genes TYMS (b, c and d) and CDKN2A (f, g and h). Green-coloured samples represent normal tissue,
and red-coloured samples represent cancer samples. In section (i) above containing (a) and (e), both normal and cancer samples show negative
staining. The lower panel presents mRNA expression data divided into four quartiles illustrating a typical outlier pattern.
doi:10.1371/journal.pone.0017259.g005
Figure 6. EC50 curves for raltitrexed and gemcitabine. EC50 curves show that the glioblastoma cell line A172 is more sensitive to raltitrexed
than gemcitabine. EC50 values were determined using the Cell Titer Glo cell proliferation assay after four days of incubation with the drugs (see Text
S1). Each data point and the standard deviations were calculated from six replicates.
doi:10.1371/journal.pone.0017259.g006
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The GTI requires gene expression data from both disease tissues
and corresponding reference samples, and approximates the
proportion of the outlying population for each gene. Our results
demonstrated that the GTI provided valuable complementary
information when compared to existing analytical methods. This
was demonstrated by the identification of 29 genes with outlier
expression profiles not previously linked to glioblastoma. False
positives, for example genes with high expression in both normal
and cancer tissues, such as GFAP, [22,23] were more often
identified by the other methods such as COPA, which otherwise
also performed well. With the increasing interest in examining
outlier gene expression profiles in very large-scale meta-datasets,
the GTI should complement the discovery of oncogenic genes and
facilitate the identification of novel therapeutic targets.
When the proportion of outliers among the disease samples
becomes very small, all existing methods become increasingly
insensitive to the presence of small outlier populations. As
demonstrated by Wu et al. (2007), COPA and the OS statistic
use only cancer group samples to determine the rth percentile that
is used as a cut-off to define outliers. Naturally, both of these
methods therefore lead to the false-positive identification of
general tissue-specificity marker genes such as GFAP, which also
show high expression in the non-malignant, normal reference
group. The approach of the GTI to utilize the normal control
group for the calculation of outlier statistics therefore effectively
reduces the number of false positives identified. Moreover, if the
number of cancer samples is considerably larger than the number
of normal samples (which is typical in most gene expression
studies), COPA and OS and ORT statistics often show a
significant increase in false positives (Figure 4). The ORT method
only uses normal samples to determine the number of outliers
[13], and did not perform well with any of the large-scale
integrated datasets (Table 1 and 3). Importantly, we found that the
GTI cut-off based on both cancer and normal samples significantly
improved outlier analysis results. This improvement could explain
why the GTI performed significantly better in large-scale
integrated datasets.
We specifically explored the performance of COPA, OS, ORT,
the t-statistic and the GTI in relation to the number of samples
that were informative for a given gene. Importantly, the total
number of informative samples introduces a strong bias in
differential gene expression analysis, in particular among multi-
study microarray datasets [30]. OS and ORT scores showed a
correlation with the number of samples, pointing to such bias. The
t-statistic and GTI were less affected by the number of samples
(Table 3). For the COPA method, we found that most of the
apparent false-positive hits among the top 100 had a large number
of samples. The scaling factors used by older methods to achieve
comparability of scores across different genes are not efficient
when there are varying numbers of samples per gene present. This
represents the major drawback of all of these methods, which does
not affect the performance of the GTI. The use of the GTI is
therefore particularly recommended in all instances where
complex data structures and highly variable numbers of samples
and data points per gene are provided. Furthermore, compared to
other methods for outlier detection, our results clearly indicated
that the scaling factor used for the GTI (T/N) efficiently dealt with
the strong variation in samples per gene.
We validated the genes highlighted by the GTI using data from
immunohistochemistry and explored their value as drug targets in
glioblastoma cell lines. TYMS is a gene encoding thymidylate
synthetase, which affects the production of nucleotide building-
blocks used in DNA synthesis and repair. Thus, it is likely that fast
growing and genetically unstable cancer cells are more dependent
on TYMS function than normal cells. The immunhistochemical
staining of the corresponding protein in HPA [24] demonstrated
that TYMS is differentially expressed between normal and cancer
samples (Figure 5), and indeed follows a characteristic outlier
profile as predicted by the GTI. We also demonstrated that
specific inhibitors of TYMS protein, such as raltitrexed, clearly
showed cancer specificity, although we did not distinguish
differential sensitivity among different tumour lines corresponding
with the level of over-expression. Immortalized normal foetal
astrocytes (SVGp12) were 4- to 2-fold less sensitive to raltitrexed
than the four cancer cell lines tested, which all expressed similarly
high levels of TYMS. We propose that the combination of outlier
expression with knowledge of possible approved or experimental
drugs based on information available from DrugBank [29] will
open a possibility to reposition known drugs to cancer types for
which they have not been previously used.
In order to better analyze heterogeneous large-scale microarray
datasets, we developed the gene tissue index (GTI) as a new robust
method for detecting cancer gene outliers. The GTI was used to
examine over-expression and under-expression in cancer tissues as
compared to a reference group. Our simulation results demon-
strated that the GTI performs well as an alternative method for
identifying outliers using single study datasets. Using a large-scale
glioblastoma clinical dataset originating from multiple laborato-
ries, the GTI identified more oncogene outliers than all of the
previously described methods. Compared with most existing
methods for outlier analysis, the GTI can uncover outliers by
determining a cut-off based on all samples (both cancer and
normal) and standardizing the score to achieve better compara-
bility across genes. Most top-ranking genes according to the GTI
showed a significant association with cancer.
Supporting Information
Figure S1 Expression profiles of GTI top ranking genes
from the simulation study. Plots of expression values in each
group, for 12 genes ranked highest by the GTI statistic. Points
have been jittered in the vertical direction for clear viewing. The
blue colour refers to the normal and red to the cancer group. In
the first plot with a GTI score of 6.906, it can be seen that the
cancer group has a sub-population with expression above 9.
(PDF)
Table S1 Single study simulations data used to construct the
receiver operating characteristic (ROC) curves.
(XLS)
Table S2 Twenty nine genes uniquely identified by GTI among
the top 100 that were further followed up in this study.
(XLS)
Text S1 R programming code of the GTI algorithm introduced
in this study used to identify cancer outliers.
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